BR112020004778A2 - usos de um composto abx196 e de uma composição farmacêutica - Google Patents

usos de um composto abx196 e de uma composição farmacêutica Download PDF

Info

Publication number
BR112020004778A2
BR112020004778A2 BR112020004778-3A BR112020004778A BR112020004778A2 BR 112020004778 A2 BR112020004778 A2 BR 112020004778A2 BR 112020004778 A BR112020004778 A BR 112020004778A BR 112020004778 A2 BR112020004778 A2 BR 112020004778A2
Authority
BR
Brazil
Prior art keywords
bladder
treatment
abx196
antibody
bladder cancer
Prior art date
Application number
BR112020004778-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Sandrine CRABE
Didier Scherrer
Hartmut Ehrlich
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of BR112020004778A2 publication Critical patent/BR112020004778A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112020004778-3A 2017-09-13 2018-09-13 usos de um composto abx196 e de uma composição farmacêutica BR112020004778A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
EM17306182.1 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

Publications (1)

Publication Number Publication Date
BR112020004778A2 true BR112020004778A2 (pt) 2020-10-13

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004778-3A BR112020004778A2 (pt) 2017-09-13 2018-09-13 usos de um composto abx196 e de uma composição farmacêutica

Country Status (18)

Country Link
US (1) US11266667B2 (https=)
EP (1) EP3681512B1 (https=)
JP (1) JP7214718B2 (https=)
KR (1) KR102706165B1 (https=)
CN (1) CN111182907B (https=)
AU (1) AU2018332046B2 (https=)
BR (1) BR112020004778A2 (https=)
CA (1) CA3075443A1 (https=)
CU (1) CU20200020A7 (https=)
DK (1) DK3681512T3 (https=)
ES (1) ES2893549T3 (https=)
HR (1) HRP20211351T1 (https=)
IL (1) IL273054B2 (https=)
MX (1) MX394216B (https=)
PL (1) PL3681512T3 (https=)
PT (1) PT3681512T (https=)
WO (1) WO2019053142A1 (https=)
ZA (1) ZA202001435B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207135B2 (en) * 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
HK1197068A1 (en) * 2011-01-05 2015-01-02 台湾大学 Methods for preparation of glycosphingolipids and uses thereof
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer

Also Published As

Publication number Publication date
US20200230163A1 (en) 2020-07-23
RU2020109889A3 (https=) 2022-01-28
AU2018332046A1 (en) 2020-03-19
HRP20211351T1 (hr) 2021-11-26
JP2020533368A (ja) 2020-11-19
EP3681512B1 (en) 2021-08-04
CN111182907A (zh) 2020-05-19
ES2893549T3 (es) 2022-02-09
CA3075443A1 (en) 2019-03-21
CN111182907B (zh) 2023-01-06
WO2019053142A1 (en) 2019-03-21
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
AU2018332046B2 (en) 2024-06-13
ZA202001435B (en) 2022-07-27
PL3681512T3 (pl) 2022-01-17
MX2020002812A (es) 2020-07-21
IL273054B1 (en) 2023-01-01
JP7214718B2 (ja) 2023-01-30
KR20200102412A (ko) 2020-08-31
CU20200020A7 (es) 2020-11-30
DK3681512T3 (da) 2021-09-06
KR102706165B1 (ko) 2024-09-13
RU2020109889A (ru) 2021-09-06
PT3681512T (pt) 2021-10-06
MX394216B (es) 2025-03-24
IL273054A (en) 2020-04-30
IL273054B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
TWI890661B (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
CN109153723B (zh) 抗pd-1抗体与放射的组合治疗癌症
ES2898867T3 (es) Anticuerpos multiespecíficos para su uso en el tratamiento de un neoplasma del tracto urinario
JPWO2019189780A1 (ja) 癌の治療及び/又は予防用医薬組成物
US11826372B2 (en) Combinations including ABX196 for the treatment of cancer
KR20240130137A (ko) 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법
AU2025204816A1 (en) Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
BR112020004778A2 (pt) usos de um composto abx196 e de uma composição farmacêutica
RU2778812C2 (ru) Abx196 для применения при лечении рака мочевого пузыря
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
ES2858309T3 (es) Un agente capaz de disminuir las células T CD8 para el tratamiento del infarto de miocardio o infarto agudo de miocardio
HK40069657B (zh) 抗半乳糖凝集素-9 抗体及其用途
HK40011701A (en) Combinations including abx196 for the treatment of cancer
HK40011701B (en) Combinations including abx196 for the treatment of cancer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]